pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
14d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
15d
MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy
fda medwatch
15d
FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
fda press
15d
Ballot measures affirm divisions over abortion and transgender issues
stat
15d
STAT+: Two No Surprises Act arbitrators lose government contracts to decide payment disputes
stat
15d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
15d
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
biopharma dive
15d
Revolution’s Rasonque off to best cancer drug launch ‘in history’
biopharma dive
15d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
15d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
15d
STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
stat
16d
STAT+: In China, a flood of controversial clinical trials slows to a trickle
stat
16d
Agios aims to shed over 100 R&D roles this year ahead of hoped-for sickle cell disease approval
fiercebiotech
16d
A treatment revolution is underway in MASH
biospace
16d
Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis
fiercebiotech
16d
Experts call for streamlined EU AI framework, urge greater literacy
raps
16d
FDA official expects user fee reauthorization despite midterm shakeup
raps
16d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
16d
Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
biospace
17d
Madrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety cover-up
fiercebiotech
17d
Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
fiercebiotech
17d
Ultragenyx shrinks workforce and axes assets to halve R&D spend
fiercebiotech
17d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
17d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
17d
Servier’s $1.6B muscular dystrophy bet on Edgewise delivers quick-fire pivotal failure
fiercebiotech
17d
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
biopharma dive
17d
STAT+: Who will get the first psychedelic approved?
stat
17d
STAT+: Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more
stat
17d
Neurocrine defends Prader-Willi drug after another patient death
biospace
17d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
← prev
page 6 of 52
next →